Article: Nicotinamide Riboside Reduces and Prevents Chemotherapy-Induced Peripheral Neuropathy: Preclinical Findings

PrevNext
Neurological Health Neuropathy Preclinical

Nicotinamide Riboside Reduces and Prevents Chemotherapy-Induced Peripheral Neuropathy: Preclinical Findings

Synopsis

Chemotherapy often causes peripheral neuropathy with no effective treatments. This study showed that NR, which activates the NAD-dependent enzyme SIRT2, prevents and reverses nerve damage caused by cisplatin chemotherapy in mice. NR's protective effects require SIRT2 but do not reduce chemotherapy's ability to kill cancer cells—in some cases, NR may enhance cancer cell sensitivity. These findings highlight NR as a potential therapy to reduce chemotherapy nerve toxicity.

Journal

Neuro-Oncology Advances

Share

Read more

Alzheimer's Disease

Nicotinamide Riboside and Caffeine Partially Increase Energy in Alzheimer’s Disease: Preclinical Findings

Synopsis As people age, levels of NAD+, a key molecule for energy production, decline, and low NAD+ is linked to energy problems in late-onset Alzheimer’s disease (LOAD). This study tested whether...

Read more
Cardiovascular Disease

CD38 Inhibitor MK-0159 Preserves NAD+ and Protects the Heart From Ischemia/Reperfusion Injury: Preclinical Findings

Synopsis The enzyme CD38 breaks down important molecules like NAD+ and NADP+, which are vital for cellular energy production and mitochondrial health. When CD38 activity increases—such as during a...

Read more